Medtronic raised guidance. Medtronic stock gains 3.08 percent

Published on 10/26/2026 at 10:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medtronic raised fiscal 2027 guidance after USD 9.76 billion revenue. Medtronic stock costs EUR 85.43 on October 26, 2026, 3.08 percent above Xetra close.

Guidance and valuation

On September 1, 2026, Medtronic reported fiscal first-quarter revenue of USD 9.76 billion and raised its outlook.
Fiscal 2027 adjusted EPS guidance stands at USD 5.94-6.00.
Medtronic stock trades at EUR 85.43 at 10:40 a.m. CET at Lang & Schwarz on October 26, 2026, 3.08 percent above the Xetra close of October 23, 2026.
Medtronic's market capitalization was USD 122.0 billion as of October 23, 2026.

Editorialfoto eines Trading-Floors mit Händlern und Kursdiagrammen im Hintergrund — Medtronic plc (ISIN IE00BTN1Y115) Börsen-Editorial zeigt Trading-Floor der NYSE mit Kursdiagrammen im Hintergrund lebhaft, Illustration mit AI erstellt.

Medtronic plc (ISIN IE00BTN1Y115) was trading at EUR 85.43 at Lang & Schwarz on October 26, 2026, at 10:40 a.m. CET, up 3.08 percent versus the Xetra close of October 23, 2026, at EUR 82.88. The move follows the medical-device group's stronger fiscal first-quarter performance and higher full-year outlook announced on September 1, 2026.

Guidance gives earnings a lift

According to Medtronic, revenue reached USD 9.76 billion in the first quarter of fiscal 2027, up 13.70 percent from the prior-year quarter. Adjusted earnings per share rose to USD 1.45 from USD 1.26, while GAAP earnings per share increased to USD 1.14 from USD 0.81.

The company raised its fiscal 2027 organic revenue growth outlook to 7.25-7.75 percent from 6.75-7.25 percent. Adjusted earnings per share guidance was set at USD 5.94-6.00, giving investors a more specific benchmark for the remaining fiscal year.

What does the outlook mean for earnings?

The guidance range places execution ahead of the next full reporting cycle. MarketBeat reported that Medtronic's quarterly adjusted earnings of USD 1.45 per share exceeded the USD 1.39 consensus by USD 0.06, while revenue topped the USD 9.55 billion estimate by USD 0.21 billion.

The same report listed 18 Buy ratings, nine Holds and one Sell, with an average target of USD 102.88. That target is a separate US-dollar valuation reference and does not replace the euro price or its Xetra comparison for German investors.

Stock price and company scale

Medtronic's market capitalization was USD 122.0 billion as of October 23, 2026. Its primary listing is on the NYSE under ticker MDT, while the 52-week range was USD 73.31 to USD 106.33 on the same dated quote.

The latest annual figures provide a longer baseline: revenue was USD 36.36 billion and net income attributable to common shareholders was USD 4.80 billion in fiscal year 2026. Operating cash flow reached USD 7.33 billion in that fiscal year, compared with USD 7.04 billion in fiscal year 2025.

Three dates frame the outlook

Medtronic reported its fiscal first-quarter results on September 1, 2026, completed the MiniMed separation on October 15, 2026, and disclosed positive registry results for its Sphere-9 catheter and PulseSelect system on October 22, 2026, according to the company's dated press-release record.

At Lang & Schwarz, Medtronic stock was trading at EUR 85.43 on October 26, 2026, at 10:40 a.m. CET, 3.08 percent above the Xetra close of October 23, 2026, at EUR 82.88. The further course of trading is shown by the continuously updated real-time quote of Medtronic stock.